Metastasis Research Network (U54 Clinical Trial Not Allowed)
ID: 360881Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360881
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Metastasis Research Network (U54 Clinical Trial Not Allowed), aimed at advancing research on cancer metastasis through the establishment of specialized centers. Applicants are required to propose a cohesive scientific theme supported by two or three interdisciplinary research projects that utilize integrative system-level approaches to understand the complexities of metastasis, including factors such as early dissemination and cellular responses to therapies. This initiative is crucial for enhancing our understanding of metastasis as a systemic issue across various cancer types, including rare and pediatric cancers. The total estimated funding for this program is $6.8 million, with individual awards capped at $1.7 million, and the application deadline is expected to close on May 15, 2026. For further inquiries, interested parties can contact Joanna M. Watson, Ph.D., at 240-276-6206 or via email at watsonjo@mail.nih.gov.

    Point(s) of Contact
    Joanna M. Watson, Ph.D.
    (240) 276-6206
    Email: watsonjo@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Forecast to Publish a Notice of Funding Opportunity for The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Metastasis Research Network (MetNet), specifically targeting research projects under the U01 Clinical Trial Not Allowed funding mechanism. This initiative aims to solicit applications that utilize integrative systems-level approaches to address critical questions in metastasis research, aligning with the ongoing efforts of the MetNet, which focuses on understanding the complex dynamics of metastasis through collaborative research. The anticipated NOFO is expected to be published in Summer 2025, with applications due in Fall 2025, and will support approximately 10 awards, with no cost-sharing or matching requirements. For further inquiries, interested applicants can contact Joanna M. Watson, Ph.D., at watsonjo@mail.nih.gov or by phone at 240-276-6206.
    Cancer Intervention and Surveillance Modeling Network (CISNET) (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Cancer Intervention and Surveillance Modeling Network (CISNET) through a Notice of Funding Opportunity (NOFO) aimed at collaborative research projects utilizing simulation and modeling techniques for specific cancer types. The primary objective is to develop evidence-based tools that inform efficient strategies for cancer control, focusing on comparative modeling for cancers such as bladder, breast, cervix, colon/rectum, esophagus, gastric, multiple myeloma, lung, prostate, and uterine. This initiative is crucial for enhancing cancer control efforts and improving outcomes in at-risk populations. The NIH plans to allocate approximately $9.438 million in FY 2026 to fund up to eight awards, with applications due by February 11, 2026. Interested applicants can reach out to Natasha Stout at natasha.stout@nih.gov for further information.
    Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)" aimed at fostering long-term partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). This initiative seeks to enhance cancer research by addressing disparities in cancer outcomes and promoting outreach and engagement across diverse populations. The program anticipates awarding approximately 12 cooperative agreements, with a minimum funding amount of $850,000, and key deadlines include an estimated synopsis close date of January 16, 2026, and an expected award date of September 1, 2026. For further inquiries, interested applicants can contact Dr. Sandra San Miguel-Majors at 240-276-5977 or via email at ncicpachU54@mail.nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)." This initiative invites applications aimed at improving the utility of mammalian cancer models, including organoids and tumoroids, to better represent human biology and address translational deficiencies in existing models. The funding seeks to advance cancer research by fostering innovative approaches to validate these models and enhance their clinical relevance, ultimately aiming to improve patient outcomes. Eligible applicants can receive up to $499,000 per year for a maximum of five years, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network (NCTN) - Network Group Operations Centers, which will require a U10 clinical trial. This initiative aims to provide scientific leadership for the development and implementation of multi-disciplinary, multi-institutional clinical trials targeting various cancer types and populations, focusing on late-phase treatment trials and advanced imaging studies. The funding, estimated at $99.3 million, is intended to support the conduct of essential clinical research for adults, adolescents, and children with cancer, with the NOFO expected to be published in Fall 2024 and applications due by late February 2025. For further details, applicants should prepare their submissions in advance of the anticipated award date of March 1, 2026.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)," aimed at improving the utility of mammalian cancer models in translational research. This initiative seeks projects that enhance the accuracy and application of models, such as organoids and tumoroids, to better represent human biology and inform clinical practices, addressing current limitations and fostering innovation in cancer research methodologies. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with a maximum funding amount of $499,000 per year for projects not exceeding five years. Interested parties should submit their applications through Grants.gov, with deadlines beginning January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for the NCI National Clinical Trials Network, specifically targeting Network Lead Academic Participating Sites through a cooperative agreement. The primary objective is to provide scientific leadership in developing and conducting multi-center clinical trials for various cancer treatments, contributing to substantial patient accrual across the NCTN. This initiative is crucial for advancing clinical research and improving treatment options for diverse patient populations affected by cancer. The estimated total program funding is $35,100,000, with an award ceiling of $1,700,000 and approximately 35 awards expected. Interested applicants should prepare for the anticipated application due date in late February 2025, following the NOFO publication in Fall 2024.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (U10 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a funding opportunity announcement for a single-source grant aimed at establishing the NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network. This initiative seeks to partner with private institutions of higher education to conduct large-scale, multi-site clinical trials, focusing on late-phase treatment trials and advanced imaging across various cancer types, while ensuring regulatory oversight in Canada. The funding, estimated at $3.8 million, is intended to support the NCTN's efforts to enhance clinical research for diverse patient populations, with the application due in late February 2025 and the award anticipated by March 1, 2026. Interested applicants should prepare their proposals in advance of the expected NOFO publication in Fall 2024.